摘要
背景:阿尔茨海默病(AD)是一种以记忆丧失、神经炎症和氧化应激为特征的神经退行性疾病。β产量过大或清除不足导致其发病聚集和沉积,被认为是AD的主要神经病理标志。因此,降低Aβ水平,抑制Aβ诱导的神经毒性是可行的治疗方法。AD治疗的策略。枸杞传统上被用作天然抗氧化剂和抗衰老产品.然而,枸杞是否具有治疗AD的潜力尚不清楚。 方法:采用荧光透射电子显微镜和透射电子显微镜(TEM)对无果枸杞芽提取物(FWE)对Aβ原纤颤和原纤维解聚的影响进行了测定; Aβ用斑点杂交法检测寡聚体水平,MTT法和TUNEL法检测细胞活力和凋亡。检测Aβ40/42、氧化应激标志物和炎性细胞因子水平。通过相应的工具包。8个月龄的雄性APP/PS1小鼠及其年龄匹配的WT窝群用FWE或车辆口服给药(灌胃),每天4次。然后认知P采用物体识别测试和Y-迷宫测试来确定成绩.用免疫组化和免疫印迹法分别评价A型β负荷和胶质细胞病变。 结果:FWE显著抑制Aβ纤维原纤化,并对Aβ原纤维进行分类,降低Aβ寡聚体水平和Aβ诱导的神经毒性,并在体外减轻氧化应激。 奥诺拉1 Fwe能明显改善APP/PS1小鼠的认知功能,减轻Aβ负荷,减少胶质增生和炎性细胞因子的释放,减轻脑内氧化应激。 结论:Fwe是治疗AD的天然药物。
关键词: 枸杞-芽提取物,阿尔茨海默病,淀粉样蛋白-β,寡聚体,神经炎症,氧化应激。
Current Alzheimer Research
Title:Fruitless Wolfberry-Sprout Extract Rescued Cognitive Deficits and Attenuated Neuropathology in Alzheimer’s Disease Transgenic Mice
Volume: 15 Issue: 9
关键词: 枸杞-芽提取物,阿尔茨海默病,淀粉样蛋白-β,寡聚体,神经炎症,氧化应激。
摘要: Background: Alzheimer’s disease (AD) is a neurodegenerative disease featured by memory loss, neuroinflammation and oxidative stress. Overproduction or insufficient clearance of Aβ leads to its pathological aggregation and deposition, which is considered the predominant neuropathological hallmark of AD. Therefore, reducing Aβ levels and inhibiting Aβ-induced neurotoxicity are feasible therapeutic strategies for AD treatment. Wolfberry has been traditionally used as a natural antioxidant and anti-aging product. However, whether wolfberry species has therapeutic potential on AD remains unknown.
Method: The effects of fruitless wolfberry-sprout extract (FWE) on Aβ fibrillation and fibril disaggregation was measured by thioflavin T fluorescence and transmission electron microscope imaging; Aβ oligomer level was determined by dot-blot; Cell viability and apoptosis was assessed by MTT and TUNEL assay. The levels of Aβ40/42, oxidative stress biomarkers and inflammatory cytokines were detected by corresponding kits. 8-month-old male APP/PS1 mice and their age-matched WT littermates were treated with FWE or vehicle by oral administration (gavage) once a day for 4 weeks. Then the cognitive performance was determined using object recognition test and Y-maze test. The Aβ burden and gliosis was evaluated by immunostaining and immunoblotting, respectively.
Results: FWE significantly inhibited Aβ fibrillation and disaggregated the formed Aβ fibrils, lowered Aβ oligomer level and Aβ-induced neuro-cytotoxicity, and attenuated oxidative stress in vitro. Oral administration of FWE remarkably improved cognitive function, reduced Aβ burden, decreased gliosis and inflammatory cytokines release, and ameliorated oxidative stress in the brains of APP/PS1 mice.
Conclusion: These findings indicate that FWE is a promising natural agent for AD treatment.
Export Options
About this article
Cite this article as:
Fruitless Wolfberry-Sprout Extract Rescued Cognitive Deficits and Attenuated Neuropathology in Alzheimer’s Disease Transgenic Mice, Current Alzheimer Research 2018; 15 (9) . https://dx.doi.org/10.2174/1567205015666180404160625
DOI https://dx.doi.org/10.2174/1567205015666180404160625 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis and Angiogenic Inhibitors in Non Small Cell Lung Cancer
Current Angiogenesis (Discontinued) New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Ligand- and Protein-Based Modeling Studies of the Inhibitors of Human Cytochrome P450 2D6 and a Virtual Screening for Potential Inhibitors from the Chinese Herbal Medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap)
Combinatorial Chemistry & High Throughput Screening Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems
Current Pharmaceutical Design The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Increased Expression of Forkhead Box Protein 3 Gene of Regulatory T Cells in Patients with Active Tuberculosis
Inflammation & Allergy - Drug Targets (Discontinued) Neuropeptide Y and Cancer Anorexia
Current Medicinal Chemistry - Central Nervous System Agents Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Identification of Leads from Marine Seaweeds against Human β-tubulin
Letters in Drug Design & Discovery Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Modulation of Inflammatory Immune Reactions by Low-Dose Ionizing Radiation: Molecular Mechanisms and Clinical Application
Current Medicinal Chemistry Chemotherapy In Japanese Encephalitis: Are We There Yet?
Infectious Disorders - Drug Targets Neurotrophic Factor Treatment After Spinal Root Avulsion Injury
Central Nervous System Agents in Medicinal Chemistry Advances in Metabonomics on Infectious Diseases
Current Metabolomics Pathophysiological Factors which Determine the Exercise Intolerance in Patients with Juvenile Dermatomyositis
Current Rheumatology Reviews Recombinant Salmonella Vaccination Technology and Its Application to Human Bacterial Pathogens
Current Pharmaceutical Biotechnology Patient Perspectives in OMERACT Provide an Anchor for Future Metric Development and Improved Approaches to Healthcare Delivery in Connective Tissue Disease Related Interstitial Lung Disease (CTD-ILD)
Current Respiratory Medicine Reviews Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
Current Pharmaceutical Design Pre-B Cell Colony Enhancing Factor/NAMPT/Visfatin in Inflammation and Obesity- Related Disorders
Current Pharmaceutical Design